X线修复交错互补基因3多态性与肺癌预后关联性的Meta分析
|
摘要
目的综合评价X线修复交错互补基因3(XRCC3)基因rs861539位点多态性与肺癌预后的关联性。方法计算机检索Pubmed、CBM、CNKI、万方数据库和VIP数据库,搜集国内外有关rs861539位点多态性与肺癌预后的研究,检索时限均为建库至2017年1月3日。由2位研究者独立进行文献筛选、数据提取及文献质量评价后,采用Stata 12.0软件进行Meta分析。结果共纳入12篇文献,累计3 603例非小细胞肺癌患者。Meta分析结果显示:XRCC3基因rs861539位点多态性与肺癌总生存期长短无统计学关联(TT vs CC:合并HR=1.10,95%CI:0.72～1.67;CT vs CC:合并HR=1.04,95%CI:0.81～1.34;TT+CT vs CC:合并HR=1.04,95%CI:0.90～1.20)。结论尚不能认为rs861539位点多态性与肺癌预后有关,受文献数量和质量限制,该结论需更多研究予以验证。
Objective To systematically evaluate the relationship of XRCC3 polymorphisms with the prognosis of lung cancer.Methods Pubmed, CBM, CNKI, WanFang Data and VIP databases from inception to January 2017 were searched for studies about the relationship between XRCC3 polymorphisms and the prognosis of lung cancer by two investigators independently. The data extraction and assessment of bias risk were performed and meta analysis was conducted with Stata 12.0 software. Results Twelve eligible studies were included involving 3 603 patients with non-small cell lung cancer. Meta analysis results showed that there was no significant association of rs861539 variance with overall survival of lung cancer(TT vs CC: pooled HR=1.10, 95%CI:0.72-1.67; CT vs CC: pooled HR=1.04, 95%CI:0.81-1.34; TT+CT vs CC: pooled HR=1.04, 95%CI:0.90-1.20). Conclusion It has not found the association between rs861539 polymorphisms and the prognosis of lung cancer. Considering the quantity and quality limitation of the included studies, the conclusion has to be verified by more high quality studies.
Objective To systematically evaluate the relationship of XRCC3 polymorphisms with the prognosis of lung cancer.Methods Pubmed, CBM, CNKI, WanFang Data and VIP databases from inception to January 2017 were searched for studies about the relationship between XRCC3 polymorphisms and the prognosis of lung cancer by two investigators independently. The data extraction and assessment of bias risk were performed and meta analysis was conducted with Stata 12.0 software. Results Twelve eligible studies were included involving 3 603 patients with non-small cell lung cancer. Meta analysis results showed that there was no significant association of rs861539 variance with overall survival of lung cancer(TT vs CC: pooled HR=1.10, 95%CI:0.72-1.67; CT vs CC: pooled HR=1.04, 95%CI:0.81-1.34; TT+CT vs CC: pooled HR=1.04, 95%CI:0.90-1.20). Conclusion It has not found the association between rs861539 polymorphisms and the prognosis of lung cancer. Considering the quantity and quality limitation of the included studies, the conclusion has to be verified by more high quality studies.
引文
[1]de las Pe n~as R, Sanchez-Ronco M, Alberola V, et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients[J]. Ann Oncol, 2006,17(4):668-675.DOI:10.1093/annonc/mdj135.
[2]Butkiewicz D, Rusin M, Sikora B, et al.An association between DNA repair gene polymorphisms and survival in patients with resected non-small cell lung cancer[J]. Mol Biol Rep, 2011, 38(8):5231-5241. DOI:10.1007/s11033-010-0674-1.
[3]Jin ZY, Zhao XT, Zhang LN, et al. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer[J]. Genet Mol Res, 2014,13(3):7617-7625. DOI:10.4238/2014.March.31.13.
[4]Ke HG, Li J, Shen Y, et al. Prognostic significance of GSTP1, XRCC1and XRCC3 polymorphisms in non-small cell lung cancer patients[J].Asian Pac J Cancer Prev, 2012, 13(9):4413-4416.DOI:10.7314/APJCP.2012.13.9.4413.
[5]Mcshane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor MARKer prognostic studies(REMARK)[J]. Breast Cancer Res Treat, 2006, 100(2):229-235. DOI:10.1093/jnci/djy088.
[6]何斐.炎症信号通路基因多态性、环境因素及肺炎衣原体感染与原发性肺癌易感性及预后研究[D].福州:福建医科大学,2013.
[7]Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis[J]. Trials, 2007, 8:16. DOI:10.1186/1745-6215-8-16.
[8]李晓玉,何斐,叶超,等.DNA双链断裂修复基因遗传多态性与非小细胞肺癌预后的相关性[J].肿瘤防治研究,2014,41(9):1014-1020.DOI:10.3971/j.issn.1000-8578.2014.09.013.
[9]Butkiewicz D, Drosik A, Suwiński R, et al. Influence of DNA repair gene polymorphisms on prognosis in inoperable non-small cell lung cancer patients treated with radiotherapy and platinumbased chemotherapy[J]. Int J Cancer, 2012,131(7):E1100-E1108.DOI:10.1002/ijc.27596.
[10]Chen X, Sun H, Ren S, et al. Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients[J]. Clin Transl Oncol, 2012, 14(3):207-213.DOI:10.1007/s12094-012-0785-3.
[11]Osawa K, Nakarai C, Uchino K, et al. XRCC3 gene polymorphism is associated with survival in Japanese lung cancer patients[J]. Int J Mol Sci, 2012,13(12):16658-16667. DOI:10.3390/ijms131216658.
[12]Yin M, Liao Z, Huang YJ, et al. Polymorphisms of homologous recombination genes and clinical outcomes of non-small cell lung cancer patients treated with definitive radiotherapy[J]. PLoS One, 2011, 6(5):e20055.DOI:10.1371/journal.pone.0020055.
[13]Su Y, Zhang H, Xu F, et al. DNA repair gene polymorphisms in relation to non-small cell lung cancer survival[J]. Cell Physiol Biochem,2015,36(4):1419-1429. DOI:10.1159/000430307.
[14]Joerger M, Burgers SA, Baas P, et al. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy:a prospective clinical study[J]. Cancer, 2012,118(9):2466-2475. DOI:10.1002/cncr.26562.
[15]Tiseo M, Bordi P, Bortesi B, et al.ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin[J]. Br J Cancer, 2013, 108(8):1695-1703. DOI:10.1038/bjc.2013.127.
[16]Huang WY, Berndt SI, Kang D, et al. Nucleotide excision repair gene polymorphisms and risk of advanced colorectal adenoma:XPC polymorphisms modify smoking-related risk[J]. Cancer Epidemiol Biomarkers Prey, 2006,15(2):306-311. DOI:10.1158/1055-9965.EPI-05-0751.
[17]Matullo G, Palli D, Peluso M, et al. XRCC1, XRCC3, XPD gene polymorphisms, smoking and(32)P-DNA adducts in a sample of healthy subjects[J]. Carcinogenesis, 2001, 22(9):1437-1445.
[18]叶飒,王飞燕,周宏斌,等.非小细胞肺癌患者血清IL-17、VEGF水平与临床分期和预后的相关性研究[J].浙江医学,2018, 40(6):573-576.DOI:10.12056/j.issn.1006-2785.2017.40.6.2017-2377.
[19]Qiu M, Xu L, Yang X, et al. XRCC3 Thr241Met is associated with response to platinum-based chemotherapy but not survival in advanced non-small cell lung cancer[J]. PLoS One, 2013,8(10):e77005. DOI:10.1371/journal.pone.0077005.
[20]黄萌,蔡琳. XRCC3多态性与肺癌关联的Meta分析[J].福建医科大学学报,2010,44(4):265-269.
[21]李晓玉.肺癌生存影响因素、DNA双链断裂修复基因多态性与肺癌患者预后关系的流行病学研究[D].福州:福建医科大学,2014.
[22]Gazdar AF. DNA repair and survival in lung cancer-the two faces of janus[J]. New England Journal of Medicine, 2007,356(8):771-773.DOI:10.1056/NEJMp068308.
[23]Ludovini V, Floriani I, Pistola L, et al. Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine treated advanced non-small cell lung cancer patients[J]. J Thorac Oncol, 2011, 6(12):2018-2026. DOI:10.1097/JTO.0b013e3182307e1f.
[2]Butkiewicz D, Rusin M, Sikora B, et al.An association between DNA repair gene polymorphisms and survival in patients with resected non-small cell lung cancer[J]. Mol Biol Rep, 2011, 38(8):5231-5241. DOI:10.1007/s11033-010-0674-1.
[3]Jin ZY, Zhao XT, Zhang LN, et al. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer[J]. Genet Mol Res, 2014,13(3):7617-7625. DOI:10.4238/2014.March.31.13.
[4]Ke HG, Li J, Shen Y, et al. Prognostic significance of GSTP1, XRCC1and XRCC3 polymorphisms in non-small cell lung cancer patients[J].Asian Pac J Cancer Prev, 2012, 13(9):4413-4416.DOI:10.7314/APJCP.2012.13.9.4413.
[5]Mcshane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor MARKer prognostic studies(REMARK)[J]. Breast Cancer Res Treat, 2006, 100(2):229-235. DOI:10.1093/jnci/djy088.
[6]何斐.炎症信号通路基因多态性、环境因素及肺炎衣原体感染与原发性肺癌易感性及预后研究[D].福州:福建医科大学,2013.
[7]Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis[J]. Trials, 2007, 8:16. DOI:10.1186/1745-6215-8-16.
[8]李晓玉,何斐,叶超,等.DNA双链断裂修复基因遗传多态性与非小细胞肺癌预后的相关性[J].肿瘤防治研究,2014,41(9):1014-1020.DOI:10.3971/j.issn.1000-8578.2014.09.013.
[9]Butkiewicz D, Drosik A, Suwiński R, et al. Influence of DNA repair gene polymorphisms on prognosis in inoperable non-small cell lung cancer patients treated with radiotherapy and platinumbased chemotherapy[J]. Int J Cancer, 2012,131(7):E1100-E1108.DOI:10.1002/ijc.27596.
[10]Chen X, Sun H, Ren S, et al. Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients[J]. Clin Transl Oncol, 2012, 14(3):207-213.DOI:10.1007/s12094-012-0785-3.
[11]Osawa K, Nakarai C, Uchino K, et al. XRCC3 gene polymorphism is associated with survival in Japanese lung cancer patients[J]. Int J Mol Sci, 2012,13(12):16658-16667. DOI:10.3390/ijms131216658.
[12]Yin M, Liao Z, Huang YJ, et al. Polymorphisms of homologous recombination genes and clinical outcomes of non-small cell lung cancer patients treated with definitive radiotherapy[J]. PLoS One, 2011, 6(5):e20055.DOI:10.1371/journal.pone.0020055.
[13]Su Y, Zhang H, Xu F, et al. DNA repair gene polymorphisms in relation to non-small cell lung cancer survival[J]. Cell Physiol Biochem,2015,36(4):1419-1429. DOI:10.1159/000430307.
[14]Joerger M, Burgers SA, Baas P, et al. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy:a prospective clinical study[J]. Cancer, 2012,118(9):2466-2475. DOI:10.1002/cncr.26562.
[15]Tiseo M, Bordi P, Bortesi B, et al.ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin[J]. Br J Cancer, 2013, 108(8):1695-1703. DOI:10.1038/bjc.2013.127.
[16]Huang WY, Berndt SI, Kang D, et al. Nucleotide excision repair gene polymorphisms and risk of advanced colorectal adenoma:XPC polymorphisms modify smoking-related risk[J]. Cancer Epidemiol Biomarkers Prey, 2006,15(2):306-311. DOI:10.1158/1055-9965.EPI-05-0751.
[17]Matullo G, Palli D, Peluso M, et al. XRCC1, XRCC3, XPD gene polymorphisms, smoking and(32)P-DNA adducts in a sample of healthy subjects[J]. Carcinogenesis, 2001, 22(9):1437-1445.
[18]叶飒,王飞燕,周宏斌,等.非小细胞肺癌患者血清IL-17、VEGF水平与临床分期和预后的相关性研究[J].浙江医学,2018, 40(6):573-576.DOI:10.12056/j.issn.1006-2785.2017.40.6.2017-2377.
[19]Qiu M, Xu L, Yang X, et al. XRCC3 Thr241Met is associated with response to platinum-based chemotherapy but not survival in advanced non-small cell lung cancer[J]. PLoS One, 2013,8(10):e77005. DOI:10.1371/journal.pone.0077005.
[20]黄萌,蔡琳. XRCC3多态性与肺癌关联的Meta分析[J].福建医科大学学报,2010,44(4):265-269.
[21]李晓玉.肺癌生存影响因素、DNA双链断裂修复基因多态性与肺癌患者预后关系的流行病学研究[D].福州:福建医科大学,2014.
[22]Gazdar AF. DNA repair and survival in lung cancer-the two faces of janus[J]. New England Journal of Medicine, 2007,356(8):771-773.DOI:10.1056/NEJMp068308.
[23]Ludovini V, Floriani I, Pistola L, et al. Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine treated advanced non-small cell lung cancer patients[J]. J Thorac Oncol, 2011, 6(12):2018-2026. DOI:10.1097/JTO.0b013e3182307e1f.